Generation Bio lifts $100M for ‘druglike’ gene medication

Gene medication startup Generation Bio has Stray no time raising the resources it needs to take its programs forward into the dispensary, closing a $hundred mn 2nd-round financing only over a 30 days after its $25 mn series A. "We havn't chose Growth candidates at this point," Generation Bio's chief executive officerGeoff McDonough—who was previously at the helm of uncommon illness specialist Sobi—told FierceBiotech. The Inc. is emerging gene therapies under the GeneWave banner that Utilize closed-ended DNA (ceDNA) rather than viruses to deliver therapeutic proteins, that can sidestep security issues like immune reactions. The series B financing was led by Fidelity Management & study, by Invus, Deerfield Management, Casdin Capital, Foresite Capital & Leerink Partners' affiliates too taking portion. "We are delighted to have the backing of this group of specialized, long-term Businessmen who share our vision to innovate a generation of people living unaffected by geneticalillness," said McDonough.

NEA powers following-generation cell & gene medication startup Senti to $53M series A round

Fresh Enterprise Associates (NEA) has led a $53 mn bet on the aftertime of cell & gene therapies. Cell & gene therapies have started to come of age over the past year, by pioneering consents for Kite, Novartis & Spark expanding access to the technologies. Senti thinks synthetic biology holds the key to these breakthroughs. The startup's goal is to design geneticalcircuits which make cell & gene therapies smarter. Given the growing list of companies This time betting their futures on cell & gene therapies, there are plenty of possibility partners about.

Doctors are In: The age of gene medication has arrived

as mentioned in

Hauling in a $100M mega-round, gene medication startup Generation Bio builds alternative to potentially risky viral vectors

A gene medication Inc. headed up with bigwigs & backed early on with Atlas has pulled in a mega-round of $hundred mn. Generation Bio is the Boston/Cambridge upstart, & it's a Inc. which's strayed from the pack while it comes to the the method of gene medication. While its rivals in the field are buckling drop on viral cars such as adeno associated viruses (AAV), Generation Bio is taking a different route. Generation Bio tells the wish is which this technology could address the developing worry revolving around viral vectors. Generation Bio

collected by :Lucy William